TY  - JOUR
AU  - Zhao, Binghao
AU  - Qi, Hao
AU  - Wu, Jiaming
AU  - Ma, Wenbin
TI  - Cemiplimab Plus Chemotherapy Could Be a First-Line Option for Advanced and Metastatic NSCLC: Results From the Phase 3 EMPOWER-Lung 3 Part 2 Trial.
JO  - Journal of thoracic oncology
VL  - 18
IS  - 7
SN  - 1556-0864
CY  - Amsterdam
PB  - Elsevier
M1  - DKFZ-2023-01257
SP  - e72 - e73
PY  - 2023
N1  - #EA:D170#
LB  - PUB:(DE-HGF)16
C6  - pmid:37348996
DO  - DOI:10.1016/j.jtho.2023.04.001
UR  - https://inrepo02.dkfz.de/record/277073
ER  -